205935-12-2Relevant academic research and scientific papers
Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions
Boussard, Cyrille,Klimkait, Thomas,Mahmood, Naheed,Pritchard, Martin,Gilbert, Ian H.
, p. 2673 - 2676 (2007/10/03)
This paper describes an approach to prevent HIV-cell fusion by disrupting the interaction between HIV protein gp120 and CD4 receptor. The CD4 residues Phe43 and Arg59 make important interactions with gp120. Small molecule analogues were made to mimic the crucial features of these residues. The analogues were assayed using a cellular 'FIGS' assay to measure inhibition of cell fusion and caused some inhibition.
Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
-
, (2008/06/13)
The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative o thereof, wherein A, B, Ra, R1, R2, R3, and R4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; Lck and Src kinase. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
Thiazole compounds useful as inhibitors of protein kinase
-
, (2008/06/13)
The present invention provides a compound of formula I: or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. The invention also
Inhibitors of Src and Lck protein kinases
-
, (2008/06/13)
The present invention provides compounds of formula I: or a pharmaceutically acceptable derivative thereof, wherein A-B is N—O or O—N and G, R1, R2, R3, and R4 are as described in the specification. These compou
